# **Special Issue**

# The Glycobiology of Viral Infections

## Message from the Guest Editors

All mammalian cells are covered in a layer of glycoconjugates-glycoproteins and glycolipids-known as the glycocalyx. Its glycans orchestrate diverse biological processes, including cell-cell recognition, cell growth and differentiation, neoplastic transformation and cell death. The glycocalyx also serves as a barrier against viruses and other intracellular pathogens, but is often utilized by such pathogens for attachment and entry (and is sometimes enzymatically processed during the release of progeny virus). Many viruses make use of glycans as entry receptors (e.g., sialic acids, histo blood group antigens and glycosamino-glycans; caliciviruses, influenza viruses, polyomaviruses, and papilommaviruses) play critical roles in cell attachment and determining host range and tropism. The goal of this Special Issue is to highlight recent advances in the definition of parameters that guide virus- glycan binding and the impact on virus infection, and their use in the development of novel compounds with inhibitory and thus antiviral activities.

### **Guest Editors**

Prof. Dr. Mario Schelhaas

Prof. Dr. Thomas H. Peters

Prof. Dr. Laura Hartmann

Prof. Dr. Thilo Stehle

## Deadline for manuscript submissions

closed (28 February 2019)



## Viruses

an Open Access Journal by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/14503

**Viruses** 

MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 viruses@mdpi.com

mdpi.com/journal/ viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.8 CiteScore 7.3 Indexed in PubMed





## **About the Journal**

## Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

## **Editor-in-Chief**

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

## **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).